Compare VIR & XHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIR | XHR |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2019 | 2014 |
| Metric | VIR | XHR |
|---|---|---|
| Price | $10.92 | $17.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $19.43 | $15.67 |
| AVG Volume (30 Days) | ★ 1.9M | 620.3K |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 3.48% |
| EPS Growth | 17.49 | ★ 326.67 |
| EPS | N/A | ★ N/A |
| Revenue | $68,556,000.00 | ★ $1,078,500,000.00 |
| Revenue This Year | $270.22 | $3.94 |
| Revenue Next Year | N/A | $2.68 |
| P/E Ratio | ★ N/A | $95.81 |
| Revenue Growth | N/A | ★ 3.80 |
| 52 Week Low | $4.75 | $11.75 |
| 52 Week High | $11.94 | $22.06 |
| Indicator | VIR | XHR |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 29.36 |
| Support Level | $8.43 | $14.26 |
| Resistance Level | $10.67 | $19.82 |
| Average True Range (ATR) | 0.53 | 0.38 |
| MACD | -0.11 | -0.06 |
| Stochastic Oscillator | 16.19 | 10.75 |
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Xenia Hotels & Resorts Inc is a real estate investment trust that invests in premium full-service, lifestyle, and urban upscale hotels and resorts across the United States. The company owns and pursues hotels in the upscale, upper upscale, and luxury segments that are affiliated with various brands. Its hotels are operated by Marriott, along with Hilton, Hyatt, Starwood, Kimpton, Aston, Fairmont, and Loews. The firm's properties are located in various regions across the U.S.: the South Atlantic, West South Central, Pacific, Mountain, and other regions. Xenia's revenue is divided between the sale of rooms, food and beverages, and other sources.